Akari Therapeutics Plc
Datakwaliteit: 83%
AKTX
Nasdaq
Manufacturing
Chemicals
€ 3,92
▲
€ 0,04
(1,03%)
Marktkapitalisatie: 4,49 M
Prijs
€ 3,92
Marktkapitalisatie
4,49 M
Dagbereik
€ 3,77 — € 3,99
52-Weeksbereik
€ 3,25 — € 63,20
Volume
8.389
Openen € 3,83
50D / 200D Gem.
€ 8,56
54,20% below
50D / 200D Gem.
€ 24,65
84,10% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -10,57 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-71,64%
Onder sectorgemiddelde (-53,41%)
ROIC-42,93%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,19
Interest Coverage-172,75
Waardering
PE (TTM)
-0,26
Boven sectorgemiddelde (-1,48)
P/B Ratio0,20
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,3 | -1,5 |
| P/B | 0,2 | 1,6 |
| ROE % | -71,6 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -17,30 M |
| ROE | -71,64% | ROA | -35,93% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -10,57 M |
| ROIC | -42,93% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,19 |
| Interest Coverage | -172,75 | Asset Turnover | N/A |
| Working Capital | -12,62 M | Tangible Book Value | 14,26 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,26 | Forward P/E | N/A |
| P/B Ratio | 0,20 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -235,54% | ||
| Market Cap | 4,49 M | Enterprise Value | 4,49 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,00 | Revenue / Share | N/A |
| FCF / Share | -9,23 | OCF / Share | -9,23 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 61,09% |
| SBC-Adj. FCF | -13,24 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -17,30 M | -19,79 M | -10,01 M | -17,75 M | -17,42 M |
| EPS (Diluted) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -17,28 M | -21,64 M | -16,81 M | -23,09 M | -17,21 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 2,82 M | 6,98 M | 5,45 M | 9,56 M | 9,13 M |
| SG&A Expenses | 9,28 M | 9,66 M | 11,36 M | 13,53 M | 8,08 M |
| D&A | 14.000,0 | 14.000,0 | 4.000,0 | 3.708,0 | 4.126,0 |
| Interest Expense | 100.000,0 | 244.000,0 | — | — | — |
| Income Tax | -1,00 M | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 47,89 M | 50,56 M | 4,36 M | 13,83 M | 11,65 M |
| Total Liabilities | 19,56 M | 28,33 M | 4,58 M | 12,04 M | 6,09 M |
| Shareholders' Equity | 28,33 M | 22,23 M | -229.000,0 | 1,79 M | 5,55 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 0,0 | 2,60 M | 3,85 M | 13,25 M | 9,36 M |
| Current Assets | 5,46 M | 2,95 M | 4,34 M | 13,81 M | 11,63 M |
| Current Liabilities | 12,35 M | 19,91 M | — | — | — |
{"event":"ticker_viewed","properties":{"ticker":"AKTX","listing_kind":"stock","pathname":"/stocks/aktx","exchange":"Nasdaq","country":"US"}}